Research & Development
CRISPR-Cas3 technique restores dystrophin function in iPSCs from DMD patients
Researchers have developed a dual CRISPR-Cas3 gene editing technique to restore dystrophin function in induced pluripotent stem cells (iPSCs) from patients with Duchenne muscular dystrophy (DMD).
August 24, 2023
Scientists discover genetic variant linked to speed of multiple sclerosis progression
The analysis of seven million genetic variants enabled the scientists to identify a variant associated with faster disease progression.
June 30, 2023
Gut bacteria changes in preclinical Alzheimer’s suggest ways to detect, delay disease
Earlier studies found that the gut microbiomes of people with symptomatic Alzheimer’s differ from those of healthy people of the same age, but were unable to tell how early the divergence begins.
June 14, 2023
Serum assay may enable the diagnosis of neurodegenerative diseases
An assay that detects minute concentrations of alpha synuclein seeds in blood serum may enable quicker diagnosis of neurodegenerative disorders.
May 30, 2023
CND Life Sciences closes $4.5M seed financing round
The funding is intended to accelerate the commercialization of the Syn-One test that identifies abnormal alpha-synuclein aggregation in cutaneous nerves through a skin biopsy.
April 6, 2023
CND Life Sciences, Beth Israel sign agreement on skin-based testing technology for neurodegenerative diseases
The agreement with Beth Israel Deaconess Medical Center aims to solidify important technology for CND’s Syn-One Test, a skin-based test that aids the diagnosis of synucleinopathies, a family of neurodegenerative disorders.
March 22, 2023
Fluorescent RNA enables real time detection of neurodegenerative disease driver in live cells
Researchers have found an RNA structure associated with a neurodegenerative disease in live cells using a technique based on fluorescence-microscopic spectroscopy.
February 7, 2023
State of Arizona awards CND Life Sciences $4.2 million to develop neurodegenerative biosignatures library
With the funds from the Governor's Office, CND plans to develop and open the Digital Biosignatures Lab in 2023 adjacent to its headquarters, adding AI-driven image analysis and other digital tools to the company’s cutaneous neurodiagnostic technology.
December 28, 2022
Labcorp NfL test confirms neurodegenerative disease
The neurofilament light chain (NfL) blood test will allow doctors to identify and verify signs of neurodegenerative disease, enabling physicians to provide a more effective and efficient path to diagnosis and treatment for patients, the firm said.
July 12, 2022
NIH test inspects abnormal tau in cerebrospinal fluid
Abnormalities in the protein tau are at the root of more than 25 neurodegenerative conditions, including Alzheimer's disease, and better means of testing are needed, other than the analysis of postmortem brain tissue, the researchers noted.
October 16, 2019
Page 1 of 1